Editorial Commentary
DESTINY-Breast06 continues to explore HR+, HER2-negative metastatic breast cancer beyond DESTINY-Breast04
Translational Breast Cancer Research
2025;
6:
11
(24 January 2025)
Editorial Commentary
Understanding the NATALEE trial—from a methodologist stand of point
Translational Breast Cancer Research
2025;
6:
10
(24 January 2025)
Review Article
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
9
(24 January 2025)
Review Article
Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
8
(24 January 2025)
Review Article
Neurological symptom management in breast cancer meningeal carcinomatosis
Translational Breast Cancer Research
2025;
6:
7
(24 January 2025)
Review Article
Modern approaches to lymphatic surgery: a narrative review
Translational Breast Cancer Research
2025;
6:
6
(24 January 2025)
Review Article
De-escalation of axillary treatment in early breast cancer—a narrative review of current trials
Translational Breast Cancer Research
2025;
6:
5
(24 January 2025)
Review Article
Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era
Translational Breast Cancer Research
2025;
6:
4
(24 January 2025)
Review Article
Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review
Translational Breast Cancer Research
2025;
6:
3
(24 January 2025)
Original Article
Underlying factors that affect ultrasound conspicuity of breast biopsy markers: an exploratory study
Translational Breast Cancer Research
2025;
6:
2
(24 January 2025)
Editorial
Unveiling breast cancer disparities: comparative insights from Asian and Western populations
Translational Breast Cancer Research
2025;
6:
1
(24 January 2025)
Case Report
A case report of interstitial lung disease caused by HER2-positive breast cancer patient receiving two antibody-drug conjugate drugs successively
Translational Breast Cancer Research
2024;
5:
36
(31 October 2024)
Editorial Commentary
Precision medicine for breast cancer: advances and challenges
Translational Breast Cancer Research
2024;
5:
35
(31 October 2024)
Editorial Commentary
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?
Translational Breast Cancer Research
2024;
5:
34
(31 October 2024)
Review Article
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Translational Breast Cancer Research
2024;
5:
33
(31 October 2024)
Review Article
Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer
Translational Breast Cancer Research
2024;
5:
32
(31 October 2024)
Review Article
Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review
Translational Breast Cancer Research
2024;
5:
31
(31 October 2024)
Review Article
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion
Translational Breast Cancer Research
2024;
5:
30
(31 October 2024)
Review Article
Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review
Translational Breast Cancer Research
2024;
5:
29
(31 October 2024)
Review Article
Breast ultrasound knobology and the knobology of twinkling for marker detection
Translational Breast Cancer Research
2024;
5:
28
(31 October 2024)
Original Article
Passage dependence of NADH redox status and reactive oxygen species level in vitro in triple-negative breast cancer cell lines with different invasiveness
Translational Breast Cancer Research
2024;
5:
27
(31 October 2024)
Case Report
Chemotherapy-induced neutropenia management in a patient with metastatic breast cancer and Shwachman-Diamond syndrome (SDS): a case report
Translational Breast Cancer Research
2024;
5:
26
(30 July 2024)
Editorial Commentary
The optimal amino acid pattern for humans and its implications for nutrition of cancer patients
Translational Breast Cancer Research
2024;
5:
25
(30 July 2024)
Editorial Commentary
Activin A from primary breast tumors generates a pre-metastatic niche by inducing pulmonary fibrosis
Translational Breast Cancer Research
2024;
5:
24
(30 July 2024)
Editorial Commentary
Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer?
Translational Breast Cancer Research
2024;
5:
23
(30 July 2024)